secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-041260
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra reports Q3 2023 net loss of $1.9M; cash $4.4M; pipeline advances for ATR-12 and ATR-04
--------------------------------------------------------------------------------

- Net loss of $1.9M narrowed from $2.4M in Q3 2022; R&D expenses fell to $548,524 from $1.4M.
- Cash and cash equivalents of $4.4M as of Sept 30, 2023; service revenue from related party of $310,700.
- Lead program ATR-12 (Netherton syndrome) IND cleared; CRO hired; first patient enrollment expected in 2024.
- ATR-04 (EGFRi-associated rash) advancing toward IND; upcoming milestones include preclinical data and IND submission.
- Bayer joint development agreement progressing; royalty-bearing licensing agreement expected as next step.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000149315223041260/0001493152-23-041260-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000149315223041260/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041260

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer